TScan Therapeutics (NASDAQ:TCRX) Releases Quarterly Earnings Results

TScan Therapeutics (NASDAQ:TCRX) issued its quarterly earnings results on Thursday. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.06), FiscalAI reports. TScan Therapeutics had a negative net margin of 1,655.35% and a negative return on equity of 108.72%. The business had revenue of $0.59 million for the quarter, compared to the consensus estimate of $0.46 million.

TScan Therapeutics Price Performance

Shares of TScan Therapeutics stock traded down $0.01 during trading on Thursday, hitting $0.17. 281,683 shares of the stock traded hands, compared to its average volume of 717,228. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.31. The stock has a market cap of $11.66 million, a price-to-earnings ratio of -0.19 and a beta of 1.21. The firm’s fifty day moving average is $0.27 and its 200-day moving average is $0.81. TScan Therapeutics has a 52 week low of $0.17 and a 52 week high of $1.47.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TCRX. Benchmark restated a “buy” rating on shares of TScan Therapeutics in a research report on Thursday, August 13th. Lifesci Capital lowered shares of TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 2nd. Wedbush cut shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 price target for the company. in a research note on Wednesday, September 2nd. HC Wainwright lowered shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 price target on the stock. in a report on Tuesday, September 8th. Finally, Weiss Ratings lowered shares of TScan Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $2.67.

About TScan Therapeutics

TScan Therapeutics, Inc. is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer. Its approach involves genetically modifying a patient’s T cells to recognize specific cancer-related antigens, with the goal of directing the immune system to attack malignant cells. The company’s pipeline includes investigational therapies for hematologic malignancies and solid tumors. Its lead programs, TSC-100 and TSC-101, are designed to target the HA-1 antigen in patients with certain blood cancers following an allogeneic hematopoietic stem cell transplant.